Incidence and predictors of all-cause and site-specific cancer in type 2 diabetes: The Fremantle Diabetes Study

European Journal of Endocrinology

Volumn 167, Issue 4, 2012, Pages 589-599

  Magliano, Dianna J ^a,b   Davis, Wendy A ^c   Shaw, Jonathan E ^a   Bruce, David G ^c   Davis, Timothy M E ^c  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; AUSTRALIA; BREAST CANCER; CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; COLORECTAL CANCER; COMORBIDITY; CONTROLLED STUDY; DISEASE ASSOCIATION; EXERCISE; FEMALE; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; PANCREAS CANCER; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSTATE CANCER;

AGED; AGED, 80 AND OVER; AUSTRALIA; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; HOSPITALIZATION; HUMANS; INCIDENCE; LONGITUDINAL STUDIES; MALE; NEOPLASMS; ORGAN SPECIFICITY; PROGNOSIS; REGISTRIES; RISK FACTORS;

EID: 84866637441     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-12-0053     Document Type: Article

References (60)

1. El-Serag HB, Hampel H & Javadi F. The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. Clinical Gastroenterology and Hepatology 2006 4 369-380. (doi:10.1016/j.cgh. 2005.12.007)
2. Huxley R, Ansary-Moghaddam A, Berrington de Gonzalez A, Barzi F & Woodward M. Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies. British Journal of Cancer 2005 92 2076-2083. (doi:10.1038/sj.bjc. 6602619)
3. Luo W, Cao Y, Liao C & Gao F. Diabetes mellitus and the incidence and mortality of colorectal cancer: a meta-analysis of twenty four cohort studies. Colorectal Disease 2012 In press. (doi:10.1111/j.1463-1318.2011.02875.x)
4. Larsson SC, Mantzoros CS & Wolk A. Diabetes mellitus and risk of breast cancer: a meta-analysis. International Journal of Cancer 2007 121 856-862. (doi:10.1002/ijc.22717)
5. Friberg E, Orsini N, Mantzoros CS & Wolk A. Diabetes mellitus and risk of endometrial cancer: a meta-analysis. Diabetologia 2007 50 1365-1374. (doi:10.1007/s00125-007-0681-5)
6. Larsson SC, Orsini N, Brismar K & Wolk A. Diabetes mellitus and risk of bladder cancer: a meta-analysis. Diabetologia 2006 49 2819-2823. (doi:10.1007/s00125-006-0468-0)
7. Kasper JS & Giovannucci E. A meta-analysis of diabetes mellitus and the risk of prostate cancer. Cancer Epidemiology, Biomarkers & Prevention 2006 15 2056-2062. (doi:10.1158/1055-9965.EPI-06-0410)
8. Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA, Pollak M, Regensteiner JG & Yee D. Diabetes and cancer: a consensus report. CA: A Cancer Journal for Clinicians 2010 60 207-221. (doi:10.3322/caac.20078)
9. Elashoff M, Matveyenko AV, Gier B, Elashoff R & Butler PC. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology 2011 141 150-156. (doi:10.1053/j.gastro.2011.02.018)
10. Lewis JD, Ferrara A, Peng T, Hedderson M, Bilker WB, Quesenberry CP Jr, Vaughn DJ, Nessel L, Selby J & Strom BL. Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. Diabetes Care 2011 34 916-922. (doi:10.2337/dc10-1068)
11. Ruiter R, Visser LE, van Herk-Sukel MP, Coebergh JW, Haak HR, Geelhoed-Duijvestijn PH, Straus SM, Herings RM & Stricker BH. Risk of cancer in patients on insulin glargine and other insulin analogues in comparison with those on human insulin: results from a large population-based followup study. Diabetologia 2012 55 51-62. (doi:10.1007/s00125-011-2312-4)
12. Decensi A, Puntoni M, Goodwin P, Cazzaniga M, Gennari A, Bonanni B & Gandini S. Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer Prevention Research 2010 3 1451-1461. (doi:10.1158/1940-6207.CAPR-10-0157)
13. Fine JP & Gray RJ. A proportional hazards model for the subdistribution of a competing risk. Journal of the American Statistical Association 1999 94 496-509. (doi:10.1080/01621459.1999.10474144)
14. Davis TM, Bruce DG & Davis WA. Cohort Profile: The Fremantle Diabetes Study (FDS). International Journal of Epidemiology 2012 In press. (doi:10.1093/ije/dys065)
15. Davis TM, Zimmet P, Davis WA, Bruce DG, Fida S & Mackay IR. Autoantibodies to glutamic acid decarboxylase in diabetic patients from a multi-ethnic Australian community: the Fremantle Diabetes Study. Diabetic Medicine 2000 17 667-674. (doi:10.1046/j.1464-5491.2000.00359.x)
16. Fernandez RC, Driscoll TR, Glass DC, Vallance D, Reid A, Benke G & Fritschi L. A priority list of occupational carcinogenic agents for preventative action in Australia. Australian and New Zealand Journal of Public Health 2012 36 111-115. (doi:10.1111/j.1753-6405.2011.00849.x)
17. Fritschi L, Hoving JL, Sim MR, Del Monaco A, MacFarlane E, McKenzie D, Benke G & de Klerk N. All cause mortality and incidence of cancer in workers in bauxite mines and alumina refineries. International Journal of Cancer 2008 123 882-887. (doi:10.1002/ijc.23554)
18. AIHW (Australian Institute of Health and Welfare) & AACR (Australasian Association of Cancer Registries) 2008. Cancer in Australia: an overview, 2008. Cancer series no. 46. Cat. no. CAN 42. Canberra: AIHW.
19. Holman CD, Bass AJ, Rouse IL & Hobbs MS. Population-based linkage of health records in Western Australia: development of a health services research linked database. Australian and New Zealand Journal of Public Health 1999 23 453-459. (doi:10.1111/j.1467-842X.1999.tb01297.x)
20. Johnson JA, Bowker SL, Richardson K & Marra CA. Time-varying incidence of cancer after the onset of type 2 diabetes: evidence of potential detection bias. Diabetologia 2011 54 2263-2271. (doi:10.1007/s00125-011-2242-1)
21. Thiebaut AC & Benichou J. Choice of time-scale in Cox's model analysis of epidemiologic cohort data: a simulation study. Statistics in Medicine 2004 23 3803-3820. (doi:10.1002/sim.2098)
22. Jee SH, Ohrr H, Sull JW, Yun JE, Ji M & Samet JM. Fasting serum glucose level and cancer risk in Korean men and women. Journal of the American Medical Association 2005 293 194-202. (doi:10.1001/jama.293.2.194)
23. Inoue M, Iwasaki M, Otani T, Sasazuki S, Noda M & Tsugane S. Diabetes mellitus and the risk of cancer: results from a large-scale population-based cohort study in Japan. Archives of Internal Medicine 2006 166 1871-1877. (doi:10.1001/archinte.166.17.1871)
24. Ferguson RD & LeRoith D. Obesity, type 2 diabetes and cancer. In Insulin-like Growth Factors and Cancer: From Basic Biology to Therapeutics, D LeRoith (ed) pp 37-72, 2011, New York: Springer.
25. Yeh H-C, Platz EA, Wang N-Y, Visvanathan K, Helzlsouer KJ & Brancati FL. A prospective study of the associations between treated diabetes and cancer outcomes. Diabetes Care 2012 35 113-118. (doi:10.2337/dc11-0255)
26. Wideroff L, Gridley G, Mellemkjaer L, Chow WH, Linet M, Keehn S, Borch-Johnsen K & Olsen JH. Cancer incidence in a populationbased cohort of patients hospitalized with diabetes mellitus in Denmark. Journal of the National Cancer Institute 1997 89 1360-1365. (doi:10.1093/jnci/89.18.1360)
27. Lo SF, Chang SN, Muo CH, Chen SY, Liao FY, Dee SW, Chen PC & Sung FC. Modest increase in risk of specific types of cancer types in type 2 diabetes mellitus patients. International Journal of Cancer 2012 In press. (doi:10.1002/ijc.27597)
28. Turturro F, Friday E & Welbourne T. Hyperglycemia regulates thioredoxin-ROS activity through induction of thioredoxininteracting protein (TXNIP) in metastatic breast cancer-derived cells MDA-MB-231. BMC Cancer 2007 7 96. (doi:10.1186/1471-2407-7-96)
29. Vigneri P, Frasca F, Sciacca L, Pandini G & Vigneri R. Diabetes and cancer. Endocrine-Related Cancer 2009 16 1103-1123. (doi:10.1677/ERC-09-0087)
30. Larsson SC, Orsini N & Wolk A. Diabetes mellitus and risk of colorectal cancer: a meta-analysis. Journal of the National Cancer Institute 2005 97 1679-1687. (doi:10.1093/jnci/dji375)
31. La Vecchia C, Negri E, Decarli A & Franceschi S. Diabetes mellitus and colorectal cancer risk. Cancer Epidemiology, Biomarkers & Prevention 1997 6 1007-1010.
32. Watson AJ & Collins PD. Colon cancer: a civilization disorder. Digestive Diseases 2011 29 222-228. (doi:10.1159/000323926)
33. Coyle YM. Lifestyle, genes, and cancer. Methods in Molecular Biology 2009 472 25-56. (doi:10.1007/978-1-60327-492-0-2)
34. Wolin KY & Tuchman H. Physical activity and gastrointestinal cancer prevention. Recent Results in Cancer Research 2011 186 73-100. (doi:10.1007/978-3-642-04231-7-4)
35. Pahor M & Furberg CD. Calcium antagonists and cancer: causation or association? Cardiovascular Drugs and Therapy 1998 12 511-513. (doi:10.1023/A:1007706529684)
36. Boudreau DM, Koehler E, Rulyak SJ, Haneuse S, Harrison R & Mandelson MT. Cardiovascular medication use and risk for colorectal cancer. Cancer Epidemiology, Biomarkers & Prevention 2008 17 3076-3080. (doi:10.1158/1055-9965.EPI-08-0095)
37. Rosenberg L, Rao RS, Palmer JR, Strom BL, Stolley PD, Zauber AG, Warshauer ME & Shapiro S. Calcium channel blockers and the risk of cancer. Journal of the American Medical Association 1998 279 1000-1004. (doi:10.1001/jama.279.13.1000)
38. Fitzpatrick AL, Daling JR, Furberg CD, Kronmal RA &Weissfeld JL. Use of calcium channel blockers and breast carcinoma risk in postmenopausal women. Cancer 1997 80 1438-1447. (doi:10.1002/(SICI)1097-0142(19971015)80:8〈1438:: AID-CNCR11〉3.0.CO;2-6)
39. Pahor M, Guralnik JM, Ferrucci L, Corti MC, Salive ME, Cerhan JR, Wallace RB & Havlik RJ. Calcium-channel blockade and incidence of cancer in aged populations. Lancet 1996 348 493-497. (doi:10.1016/S0140-6736(96)04277-8)
40. Pahor M, Guralnik JM, Salive ME, Corti MC, Carbonin P & Havlik RJ. Do calcium channel blockers increase the risk of cancer? American Journal of Hypertension 1996 9 695-699. (doi:10.1016/0895-7061(96)00186-0)
41. Ocampo NV, Tafreshi J, Hauschild CL & Pai RG. Cardiovascular medications and risk of cancer. American Journal of Cardiology 2011 108 1045-1051. (doi:10.1016/j.amjcard.2011.05.041)
42. Schatzkin A, Hoover RN, Taylor PR, Ziegler RG, Carter CL, Albanes D, Larson DB & Licitra LM. Site-specific analysis of total serum cholesterol and incident cancer in the National Health and Nutrition Examination Survey I Epidemiologic Follow-up Study. Cancer Research 1988 48 452-458.
43. Iso H, Ikeda A, Inoue M, Sato S & Tsugane S. Serum cholesterol levels in relation to the incidence of cancer: the JPHC study cohorts. International Journal of Cancer 2009 125 2679-2686. (doi:10.1002/ijc.24668)
44. Ahn J, Lim U, Weinstein SJ, Schatzkin A, Hayes RB, Virtamo J & Albanes D. Prediagnostic total and high-density lipoprotein cholesterol and risk of cancer. Cancer Epidemiology, Biomarkers & Prevention 2009 18 2814-2821. (doi:10.1158/1055-9965.EPI-08-1248)
45. Jacobs DR Jr, Hebert B, Schreiner PJ, Sidney S, Iribarren C & Hulley S. Reduced cholesterol is associated with recent minor illness: the CARDIA Study. Coronary artery risk development in young adults. American Journal of Epidemiology 1997 146 558-564. (doi:10.1093/oxfordjournals.aje.a009314)
46. Hsing AW, Sakoda LC & Chua S Jr. Obesity, metabolic syndrome, and prostate cancer. American Journal of Clinical Nutrition 2007 86 s843-s857.
47. Van Hemelrijck M, Garmo H, Holmberg L, Walldius G, Jungner I, Hammar N & Lambe M. Prostate cancer risk in the Swedish AMORIS study: the interplay among triglycerides, total cholesterol, and glucose. Cancer 2011 117 2086-2095. (doi:10.1002/cncr.25758)
48. Jorgensen L, Heuch I, Jenssen T & Jacobsen BK. Association of albuminuria and cancer incidence. Journal of the American Society of Nephrology 2008 19 992-998. (doi:10.1681/ASN.2007060712)
49. Davis WA & Davis TM. Cardiovascular risk prediction in adults with type 1 diabetes: the Fremantle Diabetes Study. Diabetes Research and Clinical Practice 2010 90 e75-e78. (doi:10.1016/j.diabres.2010.09.015)
50. Andersson C, Vaag A, Selmer C, Schmiegelow M, Sorensen R, Lindhardsen J, Gislason GH, Kober L & Torp-Pedersen C. Risk of cancer in patients using glucose-lowering agents: a nationwide cohort study of 3.6 million people. BMJ Open 2012 2 e000433. (doi:10.1136/bmjopen-2011-000433)
51. Wright JL & Stanford JL. Metformin use and prostate cancer in Caucasian men: results from a population-based case-control study. Cancer Causes & Control 2009 20 1617-1622. (doi:10.1007/s10552-009-9407-y)
52. Azoulay L, Dell'Aniello S, Gagnon B, Pollak M & Suissa S. Metformin and the incidence of prostate cancer in patients with type 2 diabetes. Cancer Epidemiology, Biomarkers & Prevention 2011 20 337-344. (doi:10.1158/1055- 9965.EPI-10-0940)
53. Patel T, Hruby G, Badani K, Abate-Shen C & McKiernan JM. Clinical outcomes after radical prostatectomy in diabetic patients treated with metformin. Urology 2010 76 1240-1244. (doi:10.1016/j.urology.2010.03.059)
54. Sieri S, Muti P, Claudia A, Berrino F, Pala V, Grioni S, Abagnato CA, Blandino G, Contiero P, Schunemann HJ & Krogh V. Prospective study on the role of glucose metabolism in breast cancer occurrence. International Journal of Cancer 2012 130 921-929. (doi:10.1002/ijc.26071)
55. Hsu C & Saif MW. Diabetes and pancreatic cancer. Highlights from the "2011 ASCO Annual Meeting". Chicago, IL, USA; June 3-7, 2011. JOP: Journal of the Pancreas 2011 12 330-333.
56. Berster JM & Goke B. Type 2 diabetes mellitus as risk factor for colorectal cancer. Archives of Physiology and Biochemistry 2008 114 84-98. (doi:10.1080/13813450802008455)
57. Zhou XH, Qiao Q, Zethelius B, Pyorala K, Soderberg S, Pajak A, Stehouwer CD, Heine RJ, Jousilahti P, Ruotolo G, Nilsson PM, Calori G & Tuomilehto J. Diabetes, prediabetes and cancer mortality. Diabetologia 2010 53 1867-1876. (doi:10.1007/s00125-010-1796-7)
58. Bradshaw PJ, Jamrozik K, Jelfs P & Le M. Mobile Australians: a moving target for epidemiologists. Medical Journal of Australia 2000 172 566.
59. Bianchi C, Miccoli R, Daniele G, Penno G & Del Prato S. Is there evidence that oral hypoglycemic agents reduce cardiovascular morbidity/mortality? Yes. Diabetes Care 2009 32 (Suppl 2) S342-S348. (doi:10.2337/dc09-S336)
60. Ford ES. Trends in the risk for coronary heart disease among adults with diagnosed diabetes in the U.S.: findings from the National Health and Nutrition Examination Survey, 1999-2008. Diabetes Care 2011 34 1337-1343. (doi:10.2337/dc10-2251)